{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:01:34Z","timestamp":1771272094978,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T00:00:00Z","timestamp":1235347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>This retrospective comparison evaluated survival in 2 well\u2010matched cohorts of patients with neoplastic meningitis (NM) presenting with or without positive cerebrospinal fluid (CSF) cytology.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Two patient cohorts were studied: 42 individuals with (Group A) and 42 without (Group B) positive CSF cytology. Groups were matched with respect to age; primary tumor; Karnofsky performance status; site of NM disease (cranial nerves or spinal cord); treatment (radiotherapy and chemotherapy; systemic and intraventricular); and absence of CSF compartmentalization, NM\u2010related encephalopathy, and neuroradiographic bulky central nervous system disease. Primary tumor histology included breast (28 patients), non\u2010Hodgkin lymphoma (14 patients), nonsmall cell lung cancer (14 patients), melanoma (12 patients), and others (16 patients). NM at presentation revealed cranial neuropathy (40 patients) or spinal cord dysfunction (58 patients). Radiotherapy was administered to 69 patients (whole brain only in 14 patients [7 each in Groups A and B], restricted spine only in 51 patients [25 in Group A and 26 in Group B], and both whole brain and restricted spine in 4 patients [2 each in Groups A and B]). All patients received intraventricular chemotherapy and 60 (30 each in Groups A and B) received concurrent tumor\u2010specific systemic chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>The median, 3\u2010month, 6\u2010month, and 12\u2010month survival rates for patients with NM were not significantly different between those patients with positive CSF cytology (18 weeks, 83%, 33%, and 9.5%, respectively) and those without positive CSF cytology (20 weeks, 90.5%, 40.5%, and 9.5%, respectively). All patients demonstrated progressive disease and died of either NM or systemic cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>In patients with NM who were matched for known prognostic variables, the presence or absence of CSF cytology did not appear to influence survival. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24210","type":"journal-article","created":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T12:22:51Z","timestamp":1235391771000},"page":"1941-1946","source":"Crossref","is-referenced-by-count":29,"title":["Neoplastic meningitis"],"prefix":"10.1002","volume":"115","author":[{"given":"Marc C.","family":"Chamberlain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra K.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,20]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"3394","article-title":"A randomized controlled trial comparing intrathecal sustained\u2010release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz MJ","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6.1674"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.1993.11.10.1978","article-title":"Involved field radiotherapy and intra\u2010Ommaya methotrexate\/ara\u2010C in patients with AIDS\u2010related lymphomatous meningitis","volume":"11","author":"Chamberlain MC","year":"1993","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380111"},{"key":"e_1_2_6_6_2","first-page":"114","volume-title":"Survival Analysis","author":"Miller RG","year":"1981"},{"key":"e_1_2_6_7_2","volume-title":"SAS Version 8","author":"SAS Institute Inc","year":"1999"},{"key":"e_1_2_6_8_2","volume-title":"Epilog Window: Epicenter Software","author":"Epicenter Software","year":"1999"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550230037013"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3110"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.2.438"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10816"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.3171\/foc.1998.4.6.7"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.561"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.10.1655"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000145599.06491.71"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.6004\/jnccn.2005.0038","article-title":"Central nervous system cancers: clinical practice guidelines in oncology","volume":"3","author":"Brem SS","year":"2005","journal-title":"J Natl Compr Canc Netw."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.29.10.1369"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.56.653.149"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.4.1173"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24210","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:04:33Z","timestamp":1760263473000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24210"}},"subtitle":["Survival as a function of cerebrospinal fluid cytology"],"short-title":[],"issued":{"date-parts":[[2009,4,20]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1002\/cncr.24210"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24210","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,20]]}}}